Results 101 to 110 of about 68,751 (311)

Small airway dysfunction and flow and volume bronchodilator responsiveness in patients with chronic obstructive pulmonary disease

open access: yes, 2015
Roberta Pisi,1 Marina Aiello,1 Andrea Zanini,2 Panagiota Tzani,1 Davide Paleari,3 Emilio Marangio,1 Antonio Spanevello,2,4 Gabriele Nicolini,5 Alfredo Chetta1 1Department of Clinical and Experimental Medicine, University of Parma, Parma, 2Division of ...
Pisi R   +8 more
core  

The effect of oral corticosteroids on bronchodilator responses in COPD

open access: yes, 1998
There have been suggestions that corticosteroid treatment might improve bronchodilator responses in chronic obstructive pulmonary disease (COPD). We have studied bronchodilator responses to salbutamol and to oxitropium bromide in 20 patients with stable ...
Rees, P.J., Corden, Z.
core   +1 more source

Combination bronchodilator therapy in the management of chronic obstructive pulmonary disease

open access: yesRespiratory Research, 2013
Chronic obstructive pulmonary disease (COPD) represents a significant cause of global morbidity and mortality, with a substantial economic impact. Recent changes in the Global initiative for chronic Obstructive Lung Disease (GOLD) guidance refined the ...
D. Tashkin, G. Ferguson
semanticscholar   +1 more source

Prevalence of Type 2 Inflammation in Chronic Obstructive Pulmonary Disease Patients With Frequent Exacerbations

open access: yes
Allergy, EarlyView.
Mireille C. Melles   +5 more
wiley   +1 more source

Endothelium‐ and epithelium‐derived novel endogenous catecholamines as modulators of the autonomic nervous system

open access: yesBritish Journal of Pharmacology, EarlyView.
Abstract Catecholamines are classically viewed as neuronal transmitters and adrenal hormones; however, accumulating evidence demonstrates that sources other than nerve fibres and adrenal medulla play a fundamental role in local organ regulation. Physiological paradoxes, such as preserved organ function after denervation or transplantation, challenge a ...
Mariana G. de Oliveira   +3 more
wiley   +1 more source

Imidafenacin, An Orally Active Muscarinic Receptor Antagonist, Improves Pulmonary Function In Patients With Chronic Obstructive Pulmonary Disease: A Multicenter, Randomized, Double-Blind, Placebo-Controlled 3×3 Crossover Phase II Trial

open access: yesInternational Journal of COPD, 2019
Kentaro Machida,1,* Tomotaka Kawayama,2,* Masaharu Kinoshita,3,* Masakazu Ichinose,4 Tohru Tsuda,5 Shohei Takata,6 Hiroshi Koto,7 Makoto Yoshida,8 Yoshinori Ashihara,9 Masaru Kawashima,10 Hideaki Suna,10 Hiromasa Inoue1 1Department of Pulmonary Medicine,
Machida K   +11 more
doaj  

Two versus four puffs of albuterol: does dose change bronchodilator response?

open access: yes, 2019
Anne V McLaughlin,1,2 Anita Bhandari,3 Craig M Schramm1,2 1Department of Pediatric Pulmonary Medicine, Connecticut Children’s Medical Center, Hartford, CT, USA; 2Department of Pediatrics, University of Connecticut School of Medicine, Farmington, CT,
Bhandari A, Schramm CM, McLaughlin AV
core  

Remote Monitoring of Inhaled Bronchodilator Use and Weekly Feedback about Asthma Management: An Open-Group, Short-Term Pilot Study of the Impact on Asthma Control

open access: yesPLoS ONE, 2013
Objective Adequate symptom control is a problem for many people with asthma. We asked whether weekly email reports on monitored use of inhaled, short-acting bronchodilators might improve scores on composite asthma-control measures.
D. Van Sickle   +3 more
semanticscholar   +1 more source

Agonist‐specific conformational dynamics at the β2‐adrenoceptor dictate allosteric modulation of Gαs signalling and bronchodilation

open access: yesBritish Journal of Pharmacology, EarlyView.
Abstract Background and Purpose β2‐adrenoceptor (β2AR) agonists are the cornerstone of asthma therapy and promote bronchodilation through Gαs signalling in airway smooth muscle (ASM), but their efficacy is limited by β‐arrestin‐mediated β2AR desensitization.
Sushrut D. Shah   +7 more
wiley   +1 more source

Efficacy and safety of twice-daily glycopyrrolate in patients with stable, symptomatic COPD with moderate-to-severe airflow limitation: the GEM1 study

open access: yesInternational Journal of COPD, 2016
Craig LaForce,1 Gregory Feldman,2 Selwyn Spangenthal,3 Joerg H Eckert,4 Michelle Henley,5 Francesco Patalano,4 Peter D’Andrea5 1North Carolina Clinical Research, Raleigh, NC, USA; 2South Carolina Pharmaceutical Research, Spartanburg, SC, USA ...
LaForce C   +6 more
doaj  

Home - About - Disclaimer - Privacy